Earnings summaries and quarterly performance for SLRX.
Executive leadership at SLRX.
Board of directors at SLRX.
Research analysts who have asked questions during SLRX earnings calls.
HD
Hunter Diamond
Diamond Equity Research LLC
3 questions for SLRX
Also covers: BHST, GFAI, GNS +1 more
AD
Ahu Demir
Ladenburg Thalmann & Co. Inc.
2 questions for SLRX
Also covers: CLRB, CYCC, IMCR
AD
Ahu Demir
Ladenburg Thalmann
2 questions for SLRX
Also covers: AADI, CYCC, IMCR
Aydin Huseynov
Ladenburg Thalmann
1 question for SLRX
Also covers: ARDX, CAPR, CLRB +3 more
MK
Mike King
H.C. Wainwright & Co., LLC
1 question for SLRX
Recent press releases and 8-K filings for SLRX.
Salarius Pharmaceuticals Announces Pricing and Closing of $7 Million Public Offering
SLRX
M&A
New Projects/Investments
- Salarius Pharmaceuticals, Inc. announced the pricing of an underwritten public offering for gross proceeds of approximately $7 million.
- The offering, which closed on November 12, 2025, included 2,514,335 shares of common stock and 2,152,331 pre-funded warrants, each with accompanying Series A and Series B Warrants.
- The combined public offering price was $1.50 per share of common stock and accompanying warrants, and $1.4999 per pre-funded warrant and accompanying warrants.
- The company received net proceeds of approximately $6.3 million from the offering, which it plans to use for clinical development of research and development programs (including those of Decoy Therapeutics), to pay off certain of Decoy's outstanding promissory notes, and for general corporate purposes.
Nov 13, 2025, 9:08 PM
Salarius Pharmaceuticals Prices $7 Million Offering Ahead of Decoy Therapeutics Merger
SLRX
M&A
New Projects/Investments
- Salarius Pharmaceuticals (NASDAQ: SLRX) announced the pricing of a $7 million underwritten public offering.
- The offering includes 2.51 million shares of common stock and 2.15 million pre-funded warrants, along with Series A and Series B Warrants to purchase up to 9.33 million shares in aggregate.
- Net proceeds from the offering will be directed towards advancing joint R&D programs, retiring Decoy's promissory notes, and strengthening working capital in anticipation of the planned merger with Decoy Therapeutics Inc..
Nov 12, 2025, 4:00 PM
Salarius Pharmaceuticals Prices $7 Million Public Offering
SLRX
M&A
New Projects/Investments
- Salarius Pharmaceuticals announced the pricing of an underwritten public offering for gross proceeds of approximately $7 million.
- The offering includes 2,514,335 shares of common stock and 2,152,331 pre-funded warrants, with a combined public offering price of $1.50 per share (or $1.4999 per pre-funded warrant) and accompanying warrants.
- The closing of the offering, expected around November 12, 2025, is contingent on the consummation of the company's proposed business combination with Decoy Therapeutics Inc..
- Net proceeds from the offering will be used to advance clinical development of research and development programs for both Salarius and Decoy, pay off certain promissory notes of Decoy, and for general corporate purposes.
Nov 11, 2025, 2:18 PM
Salarius Pharmaceuticals Regains Nasdaq Compliance
SLRX
Delisting/Listing Issues
M&A
- Salarius Pharmaceuticals, Inc. (SLRX) regained compliance with all Nasdaq listing requirements as of October 10, 2025, specifically the Equity Standard Requirement.
- This follows the company's regaining compliance with the Minimum Bid Price Requirement on September 9, 2025.
- The company will be subject to a Mandatory Panel Monitor for one year from October 10, 2025.
- Regaining compliance is a critical step in its planned merger with Decoy Therapeutics, which was announced on January 13, 2025.
Oct 14, 2025, 12:00 PM
Salarius Pharmaceuticals Amends Merger Agreement Terms for Preferred Stock
SLRX
M&A
Convertible Preferred Issuance
- Salarius Pharmaceuticals, Inc. entered into a Fifth Amendment to its Agreement and Plan of Merger on September 17, 2025, with Decoy Therapeutics Inc. and its subsidiaries.
- The amendment modifies the conversion terms for Series A and Series B Non-Voting Convertible Preferred Stock, establishing an Initial Issuance Price of $10.50 per share as the baseline for conversion ratio adjustments in dilutive subsequent financings.
- A floor price of $3.75 per share has been set for the price protection calculation triggered by a Subsequent Financing.
- The redemption price per share of Series B Preferred Stock was changed to the Initial Issuance Price multiplied by 1,000.
Sep 18, 2025, 11:01 AM
Quarterly earnings call transcripts for SLRX.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more